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Abstract
Background: Artesunate and amodiaquine (AS&AQ) is at present the world's second most widely
used artemisinin-based combination therapy (ACT). It was necessary to evaluate the efficacy of
ACT, recently adopted by the World Health Organization (WHO) and deployed over 80
countries, in order to make an evidence-based drug policy.
Methods: An individual patient data (IPD) analysis was conducted on efficacy outcomes in 26
clinical studies in sub-Saharan Africa using the WHO protocol with similar primary and secondary
endpoints.
Results: A total of 11,700 patients (75% under 5 years old), from 33 different sites in 16 countries
were followed for 28 days. Loss to follow-up was 4.9% (575/11,700). AS&AQ was given to 5,897
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patients. Of these, 82% (4,826/5,897) were included in randomized comparative trials with
polymerase chain reaction (PCR) genotyping results and compared to 5,413 patients (half receiving
an ACT).
AS&AQ and other ACT comparators resulted in rapid clearance of fever and parasitaemia,
superior to non-ACT. Using survival analysis on a modified intent-to-treat population, the Day 28
PCR-adjusted efficacy of AS&AQ was greater than 90% (the WHO cut-off) in 11/16 countries. In
randomized comparative trials (n = 22), the crude efficacy of AS&AQ was 75.9% (95% CI 74.6–
77.1) and the PCR-adjusted efficacy was 93.9% (95% CI 93.2–94.5). The risk (weighted by site) of
failure PCR-adjusted of AS&AQ was significantly inferior to non-ACT, superior to
dihydroartemisinin-piperaquine (DP, in one Ugandan site), and not different from AS+SP or AL
(artemether-lumefantrine). The risk of gametocyte appearance and the carriage rate of AS&AQ
was only greater in one Ugandan site compared to AL and DP, and lower compared to non-ACT
(p = 0.001, for all comparisons). Anaemia recovery was not different than comparator groups,
except in one site in Rwanda where the patients in the DP group had a slower recovery.
Conclusion: AS&AQ compares well to other treatments and meets the WHO efficacy criteria for
use against falciparum malaria in many, but not all, the sub-Saharan African countries where it was
studied. Efficacy varies between and within countries. An IPD analysis can inform general and local
treatment policies. Ongoing monitoring evaluation is required.
Background
Artemisinin-based combination therapy (ACT) is now the
treatment of choice for uncomplicated Plasmodium falci-
parum malaria. As of February 2009, more than 80 coun-
tries worldwide have adopted ACT as first-line therapy [1].
Currently, four forms of ACT are recommended by the
World Health Organization (WHO): artemether and
lumefantrine (AL), artesunate and amodiaquine
(AS&AQ), artesunate and mefloquine (AS+MQ) and
artesunate and sulphadoxine-pyrimethamine (AS+SP)
[2]. The choice of ACT for a country or a region depends
on a number of considerations. A critical element is the
level of underlying resistance to the longer-acting partner
drug in the combination. This is particularly important for
amodiaquine (AQ) and sulphadoxine-pyrimethamine
(SP) in Africa, where both drugs have been widely used as
monotherapies.
The WHO recommends that countries use ACT, which is
at least 90% effective and introduce new forms of ACT
that are at least 95% effective after discounting reinfec-
tions (PCR-adjusted) and that the Day 28 efficacy of
respective partner drugs alone should exceed 80% [2].
Concerns have been raised over ACT including amodi-
aquine (AQ) meeting such criteria in areas where AQ has
been widely used as monotherapy. The second most
widely used ACT, AS&AQ has been adopted as first-line
treatment in 18 countries in Africa (Burundi, Cameroon,
Chad, Congo, Côte d'Ivoire, Democratic Republic of
Congo, Equatorial Guinea, Gabon, Ghana, Guinea, Libe-
ria, Madagascar, Mauritania, Sénégal, Sao Tomé & Princ-
ipe, Sierra Leone, Sudan [South], Zanzibar) and
Indonesia. The AS&AQ combinations have been available
in a non-fixed formulation (AS+AQ) as either a loose
combination or as blister-packed tablets from several
pharmaceutical companies, and more recently, as a fixed-
dose drug combination (ASAQ). Therefore, the wide-
spread use of these combinations calls for a comprehen-
sive synthesis of published and unpublished available
results to properly inform policy decisions.
The efficacy and tolerability of AS&AQ has been tested for-
mally in several clinical trials in different epidemiological
settings in Africa. Following a systematic review of pub-
lished and unpublished comparative and non-compara-
tive trials (Olliaro et al, personal communication),
investigators were contacted for individual patient data.
This resulted in a pooled multi-centred analysis ([3-24];
Bonnet  et al, unpublished data, 2004; van den Broek,
unpublished data, 2005; Cohuet et al, unpublished data,
2004; Grandesso, unpublished data, 2004), which cannot
be strictly defined as a meta-analysis since it does not
include exhaustively all the trials with AS&AQ, an element
that may introduce a selection bias. However, to date, this
analysis with 26 trials enrolling 11,700 patients mostly in
randomized comparative trials with genotyping, is the
largest analysis at the individual patient level ever com-
piled for an ACT. In addition to examining the primary
parasitological outcomes, this study also analysed the res-
olution of parasitaemia, fever, gametocytaemia and anae-
mia, and modelled risk factors for treatment failure.
Methods
Study sites, design and patients
The studies were identified through a systematic review of
comparative and non-comparative clinical trials con-Malaria Journal 2009, 8:203 http://www.malariajournal.com/content/8/1/203
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ducted in sub-Saharan Africa, using any formulation of
AS&AQ for treating uncomplicated falciparum malaria
with follow-up of at least 28 days, regardless of language
or publication status (published, unpublished, in press,
technical reports) (Olliaro et al, personal communica-
tion).
Published studies were identified through electronic
searches up to April 2007 of MEDLINE, EMBASE, LILACS,
the Cochrane Infectious Diseases Group's trials register
and the Cochrane Central Register of Controlled Trials
(CENTRAL) using the following search terms: malaria,
amodiaquine, artesunate and artemisinins. Unpublished
studies were identified through personal contacts and by
manually searching the reference lists of studies identified
by the above-mentioned methods, contacting individual
researchers working in the field, and examining WHO
records. For all studies identified, the corresponding
author was contacted and asked to provide individual
patient data.
The following aspects of methodological quality of the
received data sets/publications were assessed: generation
of allocation sequence, adequacy of concealment of the
allocation of treatment, degree of blinding, and comple-
tion of follow-up. Generation of the allocation sequence
and allocation concealment were classified as adequate,
inadequate, or unclear [25]. Blinding was classified as
open, single, or double. Losses to follow-up (regardless of
reasons) were computed and considered adequate if less
than 10%. Finally, based on the presented power calcula-
tion, sample size estimation was assessed, as was whether
an intention-to-treat analysis could be computed. The last
patient included in this analysis was enrolled in Decem-
ber 2006. Studies involving pregnant women or severe
malaria, studies performed outside sub-Saharan Africa, as
well as economic and pharmacokinetic analyses, were
excluded.
A total of 46 trials were identified, of which 42 compared
AS&AQ with other anti-malarial drugs; four were non-
comparative. Seven studies were excluded, four because
follow-up was limited to 14 days [26-29], and three
because they were not in Africa (Afghanistan, Colombia,
Indonesia) [30-32]. Of the remaining, 39 identified stud-
ies fulfilling the inclusion criteria, 14 had to be excluded
because individual patient data were not made available.
The remaining 25 studies, and a randomized comparative
trial conducted in a common site in Uganda-Apac [24]
comprised a total of 11,700 patients treated with either a
non-fixed AS+AQ (N = 4,914) or fixed ASAQ (N = 1,073).
In randomized comparative trials the AS&AQ groups
(82% N = 4,826/5,897) were compared to anti-malarial
drugs: AQ (N = 648), AS (N = 279), AS+SP (N = 1,005),
AQ+SP (N = 1,257), AL (N = 1,319), dihydroartemisinin-
piperaquine (DP, N = 463), chloroquine + SP (CQ+SP, N
= 699), or quinine + chloroquine (Q+CQ, N = 43) (Figure
1).
Treatments
AS&AQ treatment regimens. AS&AQ products were either
loose or co-blister-packed combinations, individually for-
mulated products (AS+AQ), or fixed-dose co-formula-
tions (ASAQ). In general, the loose AS+AQ were dosed
based on body weight, while in a few studies the co-blis-
ter-packed AS+AQ and the co-formulated ASAQ were
based on age and weight range.
The majority (82%, 4,914/5,987) of the patients were
treated with individually formulated AS and AQ. The tar-
get dose was AS 12 mg/kg over 3 days and AQ 30 mg/kg
over 3 days, except in Uganda where AQ was given at 25
mg/kg (10 mg/kg on Days 0 and 1 then 5 mg/kg on Day
2). The co-blister-packed AS+AQ (AS 50 mg + AQ 153 mg
base for each of the days of treatment, dose ratio = 3.1)
was used in two studies in Senegal [19,23] containing for
each of the days of treatment 1 tablet of AS 50 mg and 1
Flow chart of comparative and non comparative studies by anti-malarial drug Figure 1
Flow chart of comparative and non comparative studies by anti-malarial drug.
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of AQ 153 mg (base), dosed either by age or by weight.
When used by age, the dosing categories were: (i) <1 y: 1/
2 tablet; (ii) ≥ 1 to 6 y: 1 tablet; (iii) ≥ 7 to <13 y: 2 tablets;
(iv)  ≥ 13 y: 4 tablets. The fixed-dose combinations of
ASAQ were available as two-and three-tablet strength
products given by age. The fixed-dose combination was
also given either once or twice a day [4,5]. For the two-tab-
let strength fixed-dose combination ASAQ (paediatric AS
25 mg + AQ 67.5; adult AS 100 mg + AQ 270 mg, dose
ratio = 2.7), the dosing categories [33-35] were: (i) 0–1
months: 1/2 paediatric; (ii) 2–11 months: 1 paediatric;
(iii) 1–6 years: 2 paediatric; (iv) 7–13 years: 1 adult; and
(v) ≥ 14 years: 2 adult. For the three-tablet strength ASAQ,
age- and weight-based doses were administered once-a-
day for three days: one tablet/day for children up to 13
years of age (≤ 35 kg) or two tablets/day for adolescents
aged 14 years and above and adults (≥ 36 kg). Doses avail-
able were: infants (2 to 11 months) received AQ 25 mg/
AS 67.5 mg; young children (1 to 4 years) received AQ 50
mg/AS 135 mg; children (6 to 13 years) received 1 tablet/
day of AQ 100 mg/AS 270 mg, and adults (14 years or
more) received two tablets (AQ 100 mg/AS 270 mg) per
day [4].
Comparator treatment regimens
(i) for the ACT groups: AL (20 mg artemether/120 mg
lumefantrine given according to weight as 1 [5–14 kg], 2
[15–24 kg], 3 [25–34 kg], and 4 [≥ 35 kg] tablets given
twice daily for 3 days); DP (around 2.3 mg/kg/day dihy-
droartemisinin and 18.4 mg/kg for 3 days); AS+SP (AS 4
mg/kg/day; SP 25 mg/kg of sulphadoxine and 1.25 mg/
kg/of pyrimethamine administered in a co-formulated
tablet [SP] as a single dose)
(ii) for the non-ACT groups: AQ+SP (AQ 10 mg/kg/day
for 3 days and SP 25 mg/kg of sulphadoxine and 1.25 mg/
kg/of pyrimethamine administered in a co-formulated
tablet [SP] as a single dose); CQ (25 mg/kg chloroquine
over 3 days) and SP; AQ only (10 mg/kg/day for 3 days);
AS5 only (AS 12 mg/kg over 5 days).
Study endpoints and statistical analysis
The primary endpoint was treatment efficacy by Day 28
defined prospectively in all studies as the treated popula-
tion free of failure (PCR not adjusted: recurrence, or PCR
confirmed: recrudescence). Data were standardized in
order to be pooled and to allow for a modified intention-
to-treat analysis (mITT). Patients lost to follow-up (or
missing a weekly visit) or with any P. falciparum infection
during the follow-up were censored for the primary out-
come at the time they were last seen. Efficacy was meas-
ured using Kaplan-Meier survival analysis.
Patients were censored as non-failures when last seen if:
(a) lost to follow-up with no evidence of failure, (b) hav-
ing withdrawn consent, (c) taking a drug with anti-malar-
ial activity, (c) having another illness or being a protocol
violation, or (e) having never started the assigned treat-
ment.
A treatment failure was defined as any of the following: (i)
the development of danger signs or severe malaria or
death or drug-induced vomiting requiring rescue treat-
ment (ii) Day 2 parasitaemia > Day 0 parasitaemia, (iii)
Day 3 parasitaemia >25% of the baseline, (iv) Day 7 par-
asitaemia, and (v) a recurrent parasitaemia within 28 days
i.e. a conversion from a positive to a negative smear result
sustained to Day 28. Patients who had a treatment failure
with missing PCR samples or indeterminant PCR results
were classed as recrudescent failures to prevent from over-
estimating efficacy levels. Treatment failure was consid-
ered the sum of early and late treatment failures, as
defined by the WHO [2].
The secondary outcomes and analytical method by Day
28:
(i) Parasitaemia clearance times (negative slide)
(ii) Elevated temperature (≥ 37.5°C)
(iii) The risks of recurrence or recrudescence (using PCR)
in AS&AQ groups compared to the comparator groups
were assessed by Cox regression stratified by site in an
attempt to account for potential statistical heterogeneity
(assessments made consistently within each study but at
different times across studies), and presented as Adjusted
Hazard Ratio (AHR).
(iv) The predictors of recurrent and recrudescent infec-
tions in AS&AQ groups were similarly assessed by Cox
regression stratified by site.
(v) Gametocytaemia was defined as any positive slide for
gametocytes, and was analysed as a binary variable. The
predictors of patent gametocytaemia on admission were
assessed by logistic regression controlled by sites. The
overall cumulative incidence probability of gametocyte
appearance on Day 28 was defined as the first positive
slide during the follow-up being the censoring event and
a measured by Kaplan-Meier survival analysis. The car-
riage rates were calculated in person-week-gametocyte
(PGW), compared using the Mantel-Haenszel method to
estimate a combined odds ratio between treatments and
presented as Rate Ratio (RRMH). The risks of gametocyte
appearance post-admission were assessed by Cox regres-
sion stratified by site.
(vi) Fractional change in haemoglobin or haematocrit
between Days 0 and 7 and Days 0 and 28, and anaemiaMalaria Journal 2009, 8:203 http://www.malariajournal.com/content/8/1/203
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(the cut off was set at Hct <30% or a Hgb <10 mg/L) at
baseline and recovery (when HCT became ≥ 30% or Hgb
≥ 10 mg/L) were compared using a student-t paired anal-
ysis. Student-t test was used for comparisons between
paired mean results. Anaemia defined as <30% Hct or <10
g/dL was categorized into 4 grades [36,37]:
a. grade 1 was ≥ 10 g/dL or ≥ 30% Hct
b. grade 2 was mild (8–9.9 g/dL, or 25%–29.9% Hct)
c. grade 3 was moderate (5–7.9 g/dL, or 15%–24.9%
Hct)
d. grade 4 was severe anaemia (<5 g/dL, or <15% Hct)
Parasitaemia, fever, and gametocyte clearance times for
each treatment group were compared using the Mann-
Whitney test. The proportions of patients remaining
febrile on Day 2 or with a positive slide on Day 3 in each
treatment group were compared by logistic regression
controlled by sites.
For patients who cleared parasites, fever, or anaemia (i, ii,
vi respectively), the time of the first negative result (fol-
lowed by negative counts) was taken as time of clearance.
Patients were seen each day for as long as they stayed par-
asitaemic and thus parasite clearance could be assessed as
those who cleared 24, 48, and 72 hours after treatment
administration. However given the potential absence of
data after treatment (72 hours) for fever and parasite
clearance, multivariate analysis was focused on the pro-
portion of patients remaining parasitaemic on Day 3 in
comparative trials.
Additionally, any positive gametocyte counts (v) detected
any time after treatment start defined gametocytes car-
riage. Gametocyte carriage rate was expressed in PGW per
1,000 person-weeks followed-up calculated as the total
length of gametocyte carriage divided by the total number
of persons exposed [38].
Spearman bivariate correlation was noted rs. Confidence
intervals were calculated at 95%, and comparisons con-
sidered significant when P < 0.05. Data were analysed
using Stata v10 (Stata Corp.).
Heterogeneity
Differences in settings, age group, use of PCR, trial design
and study procedures were included in the assessment of
study heterogeneity using Cochran's Q test and the I2 test
[39].
PCR methods
PCR was performed on paired samples to compare the
parasites' genotypes and thus distinguish between new
and recrudescent infections. Allelic variation within the
merozoite surface protein 1 and 2 (MSP1 and MSP2,
respectively), and glutamate reach protein (GLURP) was
used in Angola, Congo, DRC, Kenya, Senegal, Sudan, and
Uganda [40]. MSP1 and MSP2 were analysed in Angola,
Burkina Faso, Gabon, Guinea, Madagascar, Mali, Demo-
cratic Republic of Congo (DRC), Rwanda, Sudan, Sierra
Leone, and Uganda [41,42]. MSP2 alone was used in Zan-
zibar and Uganda.
In Uganda, selected regions of the MSP1, MSP2 and 6 mic-
rosatellite markers were amplified using PCR and charac-
terized based on sequence and size polymorphisms
identified by gel electrophoresis [43].
A recrudescent infection was defined as one that matched
in size at least one allele of both the MSP1 and MSP2 loci
present in the first sample. Thus, if any clone of a polyclo-
nal primary infection was detected during a second epi-
sode, this was considered to be a recrudescence and thus
a treatment failure.
Ethical issues
All the studies had been approved by the relevant ethics
and institution review committees.
Results
Characteristics of included studies
This review extends from February 1999 in Kenya [39] to
December 2006 in Senegal [31] and included only chil-
dren aged between four and 59 months in half (13/26) of
the studies. The proportion of patients lost to follow-up
was <10% in all the included trials. A total of 11,700
patients were enrolled in 16 countries at 33 different sites.
Individually, the trials enrolled between 27 and 890
ASAQ-treated patients. The total number of patients
treated with ASAQ was 5,987, of which 82% (N = 4,896)
were enrolled in randomized comparative trials. In com-
parator arms (N = 5,713), 49% (N = 2,787) were treated
with other ACTs and 51% (N = 2,926) treated with non-
ACTs (Figure 1). The overall loss to follow-up by Day 28
was 4.9% (575/11,700).
Study design
Eighteen trials were randomized, comparative, and open
label [5-8,10-16,21,22]; Grandesso S, unpublished data,
2004; Cohuet S, unpublished data, 2004; Bonnet M,
unpublished data, 2004; van den Broek I, unpublished
data, 2005), four were single blinded [3,4,18,31], 1 was
placebo-controlled [11], and 3 were non-comparative
[9,19,23].
Twenty-two (22) of the 25 studies included applied the
Consort guidelines. In the comparative trials, methods of
assigning patients to treatments varied from not specified
(N = 6), to allocation by bloc (N = 7), age group (N = 3),Malaria Journal 2009, 8:203 http://www.malariajournal.com/content/8/1/203
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computer generation (N = 2), sequential alternation (N =
1), slip of paper (N = 1), stratified (N = 1), and variable
blocks (N = 1). Treatment allocation was double blinded
(N = 1), not reported (N = 3), not specified (N = 8), not
done (N = 1), staff blinded (N = 7), and concealed in
sealed envelopes (N = 2). In all cases, allocation was not
disclosed to investigators at study site until a patient had
given written consent to participate in the study. All treat-
ments were supervised over the three-day course. All stud-
ies considered followed patients for 28 days or more
[10,14,32], but in order to standardize the analysis, only
results up to 28 days were included.
In all the included studies, the primary treatment out-
come was treatment efficacy. In 22 trials, parasites were
genotyped to distinguish new from recrudescent infec-
tions (10,077/11,700; 86% of the patients), one of which
was not comparative (126/11,700 or 1% of the patients).
One study compared non-fixed and fixed combinations of
AS&AQ [5]. Comparative studies included 4,896 patients
on AS&AQ and 5,713 on other anti-malarials: AL in 11
sites (24%), DP in four sites (8%), AS+SP in nine sites
(18%) for ACT groups, and AQ+SP in eight sites (22%),
CQ+SP in four sites (12%), AQ in seven sites (11%), AS in
two sites (5%), and Q+CQ in one site (1%) (Figure 1).
Day 0 Hgb and Hct levels were available in 87.1% of all
the patients (10,944/11,700), 46.9% of whom (N =
4,779) on AS&AQ. The mean change in Hgb or Hct (± SD)
could be calculated using a student paired analysis in
2,405 patients (1,361 on AS&AQ), and in 5,388 patients
on Day 28 (2,753 on AS&AQ) respectively. All trials
recorded gametocyte carriage at study enrolment and dur-
ing follow-up.
Two studies were multi-centre: (i) a double-blinded com-
parison of Placebo+AQ to AS+AQ in Senegal, Gabon, and
Kenya [11]; and (ii) an open-label comparison of a fixed-
dose combination ASAQ vs. AL in Senegal (2 sites), and
Cameroon, Madagascar, and Mali (1 site each) [4]. Three
(12%, 3/25) unpublished reports from Epicentre (n = 3)
were included, and represented 5% of the total patients
(639/11,700). One study from Uganda was conducted in
four geographical areas with different transmission inten-
sities.
Demography
The majority of the patients treated with AS&AQ were
between six months to five years of age (N = 4,153, 69%,
of whom 20%, N = 1,177 were one year old or younger).
The five to 14 years olds were 22% (N = 1,307), and adults
(15 years or older), 8% (N = 449). The median age was
three years, and the range was six months to 89 years.
Most of the adults (81%, N = 364) were from Senegal.
Uganda contributed the largest percentage of children by
country (24%, N = 1,002). In randomized comparative
trials, the proportions of children less than five years of
age were 81% in both the ASAQ groups (3,918/4,826)
and the comparator groups (4,618/5,711).
The minimum patient weight was 5 kg and mean (SD)
weight was 10.7 kg (2.8) for young children, 25 kg (8.4)
in 5–14 year olds, and 54 kg (10.6) in adults. The propor-
tion of male participants was 53%, ranging from 43% in
Sierra Leone to 57% in Senegal.
Heterogeneity
While all trials had similar endpoints, there were differ-
ences in trial design, age group, and PCR genotyping, and
substantial heterogeneity was detected due to the inclu-
sion of non-comparative studies and large differences
between field sites (I2 test = 83%, p = 0.001, Cochran Q
test for heterogeneity). Therefore in an attempt to account
for statistical heterogeneity non-comparative studies were
not included in most of the analysis and all analysis were
stratified by site.
Primary efficacy outcomes
Of the 5,987 patients treated with AS&AQ, 1% (45/5,987)
were censored on Day 0 from the analysis for protocol
violation, consent withdrawal, or self-medication as pre-
defined by the mITT analysis. Of the patients treated with
AS&AQ, 1,235 were censored by Day 28 for the efficacy
analysis (Table 1).
Crude Day 28 outcomes (not PCR adjusted)
All studies (comparative and non-comparative). The
details of the Kaplan-Meier analysis for a hypothetical
cohort of 1,000 patients free of failure are shown in Table
2 for AS&AQ and comparators (ACT and non-ACT).
The overall Day 28 efficacy of AS&AQ was 78.3% (95% CI
77.2–79.4) and 75.9% (95% CI 74.6–77.1) for all trials
and comparative trials only, respectively. Efficacies of
other forms of ACT were 83.2% (95% CI 81.8–84.6), and
for non-ACT 55.8% (95% CI 54.0–57.7)(Table 2). Crude
AS&AQ efficacy varied widely across study sites (p =
0.001, log rank test), ranging from 30% (95% CI 25.4–
34.5) in Tororo, Uganda, to 100% (95% CI 97.2–100) in
Cameroon. The median (range) time to failure in AS&AQ
groups was 21 days (0–28). Efficacy by site was positively
correlated to median time to failure (rs = 0.624, p =
0.001).
PCR-adjusted Day 28 outcomes
Among AS&AQ recipients, genotyping was available in 21
randomized comparative studies at 23 sites (78% or
4,577/5,987). Of these patients, 257 had a recrudescent
infection (Table 3) of which 90% (232/257) were PCR
confirmed, 24 were danger signs or severe malaria, andMalaria Journal 2009, 8:203 http://www.malariajournal.com/content/8/1/203
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one was resulting from the clinician decision. Overall,
93.9% (95% CI 93.2–94.5) of the patients treated with
AS&AQ had cleared their primary infection and were free
of recrudescence within 28 days. The corresponding fig-
ures were for other forms of ACT 94.8% (95% CI 93.8–
95.6) and for non-ACT 80.6% (95% CI 78.8–82.0).
The WHO criterion of >90% efficacy after genotyping was
not met in 10 of 23 sites from 16 countries with PCR
results: Uganda-Amudat, Kenya-Migori, Zanzibar-Miche-
weni, Uganda-Arua, Sierra Leone-Kailahun, Uganda-Apac,
South Sudan-Nuba, Congo-Kinbanda, Rwanda-Rukara,
and DRC-Boende (Table 4). Where AS&AQ efficacy PCR-
adjusted per site was <90%, the comparator arm was
>90% in 3 sites: in Congo-Kinbanda (AL), Uganda-Amu-
dat (AS+SP), and Zanzibar-Micheweni (AL), and not sig-
nificantly superior to AS&AQ (P > 0.05 for all
comparisons, logrank test).
The mean efficacy after PCR adjustment by country (Fig-
ure 2b) was below 90% in five countries: Kenya (1 site)
89.5% (95% CI 83.4–93.5), South Sudan (2 sites) 88.4%
(95% CI 79.8–93.4), Sierra Leone (one site without com-
parator group) 88.3% (95% CI 76.6–93.1), DRC (two
sites) 87.5% (95% CI 78.5–92.9), and Congo (one site)
84.2% (95% CI 74.8–90.4). In all these countries the
upper limit of the 95% CI was >90%. Conversely, the
lower limit of the 95%CI was above 90% in seven coun-
Table 1: Censoring events by drug category for the efficacy analysis (both comparative and non-comparative studies included)
AS&AQ Other ACTs non-ACT
Criteria n%n%n%
Total 5987 100% 2787 100% 2926 100%
Censored on Day 0 - no drug intake 3
- voluntary withdrawal 19
- self-medication 10 16
- protocol violation 16 18 13
Sub-total 5942 99% 2769 99% 2897 99%
Failure Total recurrent cases 1126 91% 429 95% 1171 95%
- PCR confirmed* 203 95 436
- indeterminate* 47 47
- no PCR/no sample* 20 51 34
Danger sign/severe malaria/death* 24 2% 8 2% 1 <1%
Increased parasitaemia or >25% Day3* 45 3%
Clinician decision* 1 <1%
Drug vomiting 44 4% 6 1% <1%
Still positive when lost to follow-up* 29 2% 5 1% 13 1%
Lost result* 11 1% 3 1% 8 1%
Total 1235 100% 451 100% 1238 100%
* Classified as recrudescent failure
ACT: artemisinin combination therapy.
Table 2: Crude efficacy (not PCR-adjusted), number and quotients of failures by Day and drug categories within 28 days*
artesunate amodiaquine combinations Other ACT non-ACT
Day of 
censure
Failure 
(n)
Total 
follow-
up
Quotient 
Day(x)
Free of 
failure
Failure 
(n)
Total 
follow-
up
Quotien
t Day(x)
Free of 
failure
Failure 
(n)
Total 
follow-
up
Quotient 
Day(x)
Free of 
failure
0 77 5942 0.013 987 8 2769 0.003 997 11 2926 0.004 996
1 24 5839 0.004 983 8 2746 0.003 994 16 2912 0.005 991
2 4 5806 0.001 982 3 2736 0.001 993 22 2895 0.008 983
3 1 5774 0.000 982 1 2729 0.000 993 24 2868 0.008 975
7 5 5745 0.001 981 2 2720 0.001 992 86 2824 0.030 945
14 103 5675 0.018 964 22 2700 0.008 984 228 2703 0.084 866
21 531 5477 0.097 871 147 2653 0.055 929 491 2419 0.203 690
28 490 4874 0.101 783 260 2479 0.105 832 360 1895 0.190 559
Total 1235 5942 451 2769 1238 2926
*Note: this table does not refer to randomized comparative trials therefore direct comparisons between drug categories in this table are not 
legitimate. ACT: artemisinin combination therapy.Malaria Journal 2009, 8:203 http://www.malariajournal.com/content/8/1/203
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tries (Angola, Burkina-Faso, Cameroon, Guinea, Mada-
gascar, and Senegal).
Out of the five countries where the mean efficacy PCR-
adjusted of AS&AQ was <90%, two countries had two
studies conducted in a different site: Sudan (Malakal and
Nuba) where the mean PCR-adjusted efficacy of AS+SP of
both sites was >90% (91.7, 95%CI 85.3–96.4); and DRC
(Boende and Kamalo) where the mean PCR-adjusted effi-
cacy of AS+SP was <90% [84.7, 95%CI 76.5–89.1]).
Secondary efficacy outcomes
Parasite clearance
The overall geometric mean of parasite counts on admis-
sion (Day 0) was 21,541/μL with wide site/country varia-
tions; the geometric means ranged from 3,303/μL in
Burkina Faso to 40,492/μL in Dabola, Guinea (p = 0.001).
Using multivariate analysis based on randomized com-
parisons, and controlling by sites, higher parasitaemia
was found in younger patients (age as continuous varia-
ble) (p = 0.001), and in patients without gametocytes on
admission compared to patients with gametocytes (p =
0.001). In the randomized trials, the median parasite
clearance time for AS&AQ was Day 2 ranging from Day 1
to Day 7 in 5,853 patients (2.2% did not complete treat-
ment or were regarded as treatment failures). Time to par-
asite clearance varied from site to site (p = 0.001), and was
longer in patients with higher Day 0 parasitaemia (p =
0.001).
The proportion of patients remaining parasitaemic was
66.4% (1634/2462) on Day 1, 8.5% (440/5170) on Day
2, 1.8% (104/5460) on Day 3, and 0.6% (35/5507) on
Day 7, including recurrences (Figure 3).
The risk of being parasitaemic on Day 3 in randomized
controlled trials was not different between AS&AQ (2.9%,
90/3125) and other ACTs or AS alone (2.6%, 92/2778, p
= 0.476, weighted by site). However, patients treated with
non-ACT were at a higher risk of remaining parasitaemic
on Day 3 (16%, 415/2609, p = 0.001, weighted by site):
in AQ groups (19%, 114/611, p = 0.001, weighted by
site), in AQ+SP (8%, 103/1256, p = 0.001, weighted by
site), and in CQ+SP groups (26%, 184/699, p = 0.001,
weighted by site).
The multivariate analysis stratified by site based on rand-
omized comparisons confirmed these results: no differ-
ence between AS&AQ and comparators were found using
a three-day ACT (p > 0.268 for all comparisons). A signif-
icant better parasite clearance was seen with AS&AQ than
with non-ACT (the OR for being parasitaemic with AQ,
CQ+SP, and AQ+SP was 16.43, 73.11 and 16.71, respec-
tively, p = 0.001 for all comparisons).
Fever clearance
All patients included in the trials had fever (axillary tem-
perature ≥ 37.5°C) or a recent history of fever. For the
77.7% (4,614/5,940) AS&AQ patients who were actually
febrile on admission, the median fever clearance time was
Day 1 (Figure 3). The proportion of patients with fever
decreased to 7.4% (372/5,040, 95% CI 6.7%–8.1%) on
Day 1, 2.4% (119/4,998, 2.0%–2.8%) on Day 2, and
2.4% (102/4,308, 1.9%–2.8%) on Day 3. Three patients
were febrile on Day 21: in one patient from Guinea fever
decreased quickly on Day 2 (37.9°C) but remained
between 37.5°C and 37.9°C until Day 21, and cleared on
Day 28; two other patients who had previously cleared
fever became febrile on Day 21 and cleared on Day 28.
Based on randomized comparative studies, the propor-
tion of patients remaining febrile on Day 2 was lower in
the AS&AQ groups compared to AS5 (0.8%, 2/251 vs.
4.0%, 10/252, p = 0.020), AS+SP (1.4%, 7/487 vs. 4.1%,
Table 3: PCR-adjusted efficacy, number of failures by Day, and drug categories within 28 days (only in studies using PCR results)*
artesunate amodiaquine combinations Other ACT non-ACT
Day of 
censure
Recrud. 
(n)
total Quotient 
Day(x)
Free of 
recrud.
Recrud. 
(n)
total Quotient 
Day(x)
Free of 
recrud.
Recrud. 
(n)
total Quotient 
Day(x)
Free of 
recrud.
0 18 4577 0.004 996 4 2741 0.001 999 2637 0.000 998
1 6 4559 0.001 995 4 2740 0.001 997 6 2637 0.002 996
2 4549 0.000 995 2 2735 0.001 996 21 2630 0.008 988
3 1 4527 0.000 995 1 2730 0.000 996 20 2604 0.008 979
7 3 4508 0.001 994 2721 0.000 996 35 2565 0.014 966
14 23 4459 0.005 989 10 2701 0.004 992 89 2452 0.036 932
21 119 4292 0.027 961 32 2654 0.012 980 163 2178 0.075 862
28 87 3745 0.025 939 82 2480 0.033 948 109 1685 0.065 806
Total 257 4577 135 2741 443 2637
*Note: this table does not refer to randomized comparative trials therefore direct comparisons between the groups of this table are not legitimate. 
ACT: artemisinin combination therapy. Recrud.: recrudescenceMalaria Journal 2009, 8:203 http://www.malariajournal.com/content/8/1/203
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Table 4: AS&AQ groups: crude and PCR-adjusted Day 28 efficacy results presented by site and country
Efficacy by Day 28 by 
country and site *
Number of patients 
enrolled receiving 
ASAQ
Crude (not adjusted for reinfection) PCR-adjusted
Efficacy Lower 95% 
confidence 
interval
Upper 95% 
confidence 
interval
Efficacy Lower 95% 
confidence 
interval
Upper 95% 
confidence 
interval
Angola (all) 166 92.0% 83.0% 96.3% 98.6% 90.5% 99.8%
Angola-Caala 69 91.0% 81.1% 95.9% 98.4% 89.3% 99.8%
Angola-Kuito 97 92.9% 84.9% 96.8% 98.8% 91.7% 99.8%
Burkina Faso (all) 923 96.7% 91.4% 97.5% NA NA NA
Burkina Faso-
Bobo-Dilaossou
33 100% 91.3% 100.0% NA NA NA
Burkina Faso-
Pouytenga
890 93.5% 91.5% 95.0% 97.3% 95.9% 98.2%
Cameroun-Mendong 110 98.1% 92.5% 99.5% 100.0% 100.0% 100.0%
Congo-Kindamba# 101 67.5% 57.0% 75.9% 84.2% 74.8% 90.4%
Gabon-Lambarene 110 87.5% 79.1% 92.7% 94.5% 87.3% 97.7%
Guinea-Dabola 110 94.4% 87.9% 97.4% 99.1% 93.6% 99.9%
Kenya-Migori# 200 76.5% 69.1% 82.4% 89.5% 83.4% 93.5%
Madagascar-
Tsiroanomandidy
119 96.6% 91.2% 98.7% 99.2% 94.1% 99.9%
Mali (all) 387 74.5% 67.4% 80.4% 98.3% 94.6% 99.5%
Mali-Bancoumana 135 68.5% 59.7% 75.7% 97.5% 92.3% 99.2%
Mali-Bougoula 252 80.6% 75.1% 85.0% 99.2% 96.8% 99.8%
DRC (all) 136 74.5% 62.5% 82.0% 88.3% 76.6% 93.1%
DRC-Boende# 90 57.7% 46.5% 67.4% 78.7% 67.6% 86.4%
DRC-Kabalo 46 91.3% 78.5% 96.6% 97.8% 85.6% 99.7%
Rwanda (all) 410 82.4% 75.1% 87.5% 91.6% 85.6% 95.0%
Rwanda-Kicukiro 122 91.6% 85.0% 95.4% 95.8% 90.2% 98.2%
Rwanda-
Mashesha
150 86.7% 80.1% 91.2% 95.3% 90.3% 97.7%
Rwanda-Rukara# 138 68.8% 60.2% 75.9% 83.8% 76.1% 89.1%
Sénégal (all) 1390 96.1% 91.4% 98.5% NA NA NA
Senegal-Keur 
Socé
264 94.2% 90.9% 96.7% 99.2% 96.8% 99.8%
Senegal-
Djembeye
110 95.3% 91.3% 99.3% NA NA NA
Senegal-
Kabrousse
27 100% 89.1% 100.0% NA NA NA
Senegal-Mlomp 883 95.8% 94.4% 97.2% NA NA NA
Senegal-
Oussouye
106 95.3% 91.3% 99.3% NA NA NA
Sierra-Leone-
kailahun#
126 40.5% 31.5% 49.4% 87.5% 78.5% 92.9%
Sudan (all) 214 76.1% 66.8% 83.1% 88.4% 79.8% 93.4%
South Sudan-
Nuba#
80 63.8% 52.2% 73.2% 84.9% 74.4% 91.4%
Sudan-Malakal 134 88.5% 81.3% 93.0% 91.8% 85.3% 95.5%Malaria Journal 2009, 8:203 http://www.malariajournal.com/content/8/1/203
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20/488, p = 0.011), CQ+SP (1.5%, 7/745 vs. 4.7%, 33/
697, p = 0.001), AL (2.8%, 33/1,178 vs. 6.3%, 63/1,000,
p = 0.001). No difference was detected between AS+AQ
and AQ alone, DP, or AQ+SP and between the non-fixed
and fixed ASAQ products (p > 0.147 for all comparisons).
Risks of failure in randomized comparisons
Recurrence. The randomized comparative clinical trial
conducted in Burkina Faso did not detect any difference in
crude efficacy (PCR not adjusted) between the loose
(AS+AQ) and the fixed-dose (ASAQ) combinations (p =
0.510). Based on randomized comparative studies with
AS&AQ (N = 4,896) compared to other anti-malarial
treatments (N = 5,713) and using multivariate analysis
stratified by site (Figure 4a), patients treated with DP, AL,
and AS+SP were at lower risk of failure (p = 0.001, for all
comparisons) compared to AS&AQ, while patients treated
with AQ alone, AS5 and CQ+SP were at a higher risk (p =
0.001, for all comparisons). The risk of failure was not dif-
ferent between AS+AQ and AQ+SP (p = 0.812).
Recrudescence. In the non-AS&AQ comparator arms, gen-
otyping results were available for all studies analysed (N =
21). In Burkina Faso, no difference was detected between
the fixed-dose 95.0% (95% CI 92.7–97.3) and the non-
fixed combination 95.7% (95% CI 93.7–97.7) (p =
0.645). Based on comparative randomized trials, and
using multivariate analysis stratified by site, the risk of
failure compared with AS&AQ was (i) lower with DP (p =
0.001); (ii) higher with AQ+SP, AQ alone, AS5, and
CQ+SP (p = 0.001 for all comparisons); (iii) not different
as compared with AS+SP and AL (p = 0.346; p = 0.158,
respectively) (Figure 4b).
Uganda (all) 1283 53.3% 46.5% 59.6% 91.1% 85.1% 94.7%
Uganda-Amudat# 106 30.3% 21.3% 39.9% 89.9% 79.2% 95.2%
Uganda-Apac# 174 46.5% 38.9% 53.8% 87.2% 80.6% 91.7%
Uganda-Arua# 174 49.3% 41.7% 56.6% 88.8% 82.5% 92.9%
Uganda-Jinja 189 79.5% 72.9% 84.6% 94.3% 89.6% 96.9%
Uganda-Kampala 242 83.8% 78.4% 87.9% 95.7% 92.1% 97.7%
Uganda-Tororo 398 30.2% 25.7% 34.8% 91.1% 86.8% 94.0%
Zanzibar (all) 202 75.6% 64.9% 83.3% 91.8% 83.1% 96.2%
Zanzibar-Kivunge 148 73.5% 65.5% 79.9% 95.0% 89.7% 97.6%
Zanzibar-
Micheweni#
54 77.8% 64.2% 86.7% 88.7% 76.5% 94.7%
*Mean efficacies are given for countries with multiple sites
# Efficacy PCR adjusted <90%
NA: not applicable, no PCR genotyping data for all sites from that country
Table 4: AS&AQ groups: crude and PCR-adjusted Day 28 efficacy results presented by site and country (Continued)
Crude (A) and PCR-adjusted (B) Day 28 efficacy with ASAQ  by country stratified by site (mean and 95% CI) Figure 2
Crude (A) and PCR-adjusted (B) Day 28 efficacy with 
ASAQ by country stratified by site (mean and 95% 
CI). Note: The dotted horizontal line in panel B shows the 
WHO-recommended threshold of efficacy.
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Predictors of failure
Recurrence. In AS&AQ groups using multivariate analysis
stratified by site and controlling for potential independ-
ent factors (age, parasitaemia, and gametocyte on admis-
sion), younger children (age in continuous in terms of per
1 year increase of age AHR = 0.93, 95% CI 0.90–0.97, p =
0.001), and anaemic compared to non-anaemic patients
were at a higher risk of failure (AHR = 1.17, 95% CI 1.02–
1.35, p = 0.022). Likewise, when reinfections (PCR con-
firmed) were included for analysis, younger (AHR = 0.96,
95% CI 0.92–0.99, p = 0.023) and anaemic patients (AHR
= 1.21, 95% CI 1.04–1.42, p = 0.014) were at higher risks.
Recrudescence. The median time to recrudescence (PCR
confirmed) with AS&AQ was Day 21. Using similar anal-
ysis as previously, younger patients were also at higher risk
for recrudescence (AHR = 0.88, 95% CI 0.81–0.95, p =
0.001), and no other independent factor was detected.
Gametocytaemia
On admission. In AS&AQ groups, the prevalence rate of
gametocytaemia on admission was 12.9% (95% CI 5.4%–
20.5%), ranging from 0% in Zanzibar-Micheweni and
Cameroon-Mendong, to 51.7% in Uganda-Apac. Using
multivariate analysis and controlling for site, younger
patients (p = 0.001) and patients with lower parasitaemia
(p = 0.001) were at a higher risk for gametocytaemia on
admission. The overall cumulative incidence probability
of gametocyte presence on Day 28 was 31.4% (95% CI
22.7–39.7). The peak of gametocyte prevalence was on
Day 2 (19.3%, 677/3,516). The gametocyte carriage rate
was 71 PGW per 1,000 weeks of follow-up, and the mean
duration per patient was 14.5 (SD ± 11.7) days. In
patients who did not have gametocytes on admission, the
cumulative probability was 20.4% (95% CI 18.3–22.5),
and the gametocyte carriage was 36/1,000 PGW. The
mean duration was 6.2 (SD ± 2.5) days, and the maxi-
mum incidence rate was reached on Day 2: 10.4% (95%
CI 9.3–11.5) when 48% of the cases occurred (Figure 5).
Gametocyte clearance. The overall median clearance time
was Day 14 in patients treated with AS&AQ, and varied
widely by site (ranging from Day 1 to 28). Clearance time
could not be calculated for 7.7% (46/594) of the patients
with gametocytes on admission who had been lost to fol-
low-up or censored due to failure, leaving 548 patients for
the analyses on Day 28 (all having cleared their gameto-
cytes by then). There was no difference in clearance time
Overall risks of failure of artesunate-amodiaquine by compa- rator: (A) crude, (B) PCR-adjusted Day 28 outcome. Figure 4
Overall risks of failure of artesunate-amodiaquine by 
comparator: (A) crude, (B) PCR-adjusted Day 28 
outcome. Note: The forest plot represents the risk of fail-
ure of artesunate amodiaquine versus comparators in rand-
omized comparative studies. Results were stratified by site. 
The size of boxes is proportional to the number of patients 
included. The square represents the adjusted hazard ratio 
and 95% CI.
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between patients who had gametocytes on admission and
those who developed gametocytaemia post-admission (p
= 0.378). However, while the peak time to clearance was
Day 14 for the patients who did not have gametocyte on
admission (32%), gametocyte clearance for those who
had gametocytes on admission was almost evenly distrib-
uted throughout treatment and follow-up (20% on Day 2
and Day 21) (Figure 6).
Results by drug treatment. Using survival analysis to
examine the cumulative probability of gametocyte
appearance in patients who did not have gametocytes on
admission, and measuring levels of carriage expressed in
PGW by site, different profiles were obtained depending
on the anti-malarial used. No difference in gametocyte
appearance was detected between the loose and fixed
AS&AQ combinations (AHR = 1.07, p = 0.587).
Overall, using multivariate analysis based on randomized
comparative studies and stratified by site (Figure 7), the
risk of gametocyte appearance post-admission compared
to AS&AQ groups was higher with AQ (AHR = 2.59, p =
0.001), CQ+SP (AHR = 2.29, p = 0.001), and AQ+SP
(AHR = 1.77, p = 0.001); lower with AL (AHR = 0.57, p =
0.001) and DP (AHR = 0.39, p = 0.001); and not different
with AS+SP (AHR = 0.88, p = 0.288).
Gametocyte carriage rate in patients without gametocyte
on admission in randomized comparative trials.
No difference was detected between the loose and the
fixed AS&AQ combinations in Burkina Faso (p = 0.824).
The overall carriage rate was 57% shorter with AL (13/
1000 PGW) compared with AS&AQ (27/1000 PGW,
RRMH [Mantel-Haenszel rate ratio] = 0.48, 95% CI 0.31–
0.63, p = 0.001)(Figure 8). However, results by site
showed that AL was only superior to AS+AQ (RR = 0.05,
95% CI 0.01–0.14, p = 0.001) in one site in Uganda (out
of 3 Ugandan sites, and not in the other sites). Compared
with DP groups in Rwanda, no difference in gametocyte
carriage was detected compared to AS+AQ (p = 0.817). As
a result, the overall carriage rate was 70% shorter in DP
groups (RRMH = 0.25, 95% CI 0.11–0.41, p = 0.001,
weighted by site). However, the carriage rate was only sig-
nificantly lower in DP compared to AS&AQ groups in one
Ugandan site (RR = 0.12, 95% CI 0.06–0.26, p = 0.001).
Gametocyte clearance time distribution in AS&AQ groups in  patients with and without gametocyte on admission Figure 6
Gametocyte clearance time distribution in AS&AQ 
groups in patients with and without gametocyte on 
admission.
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Overall risks of gametocyte appearance in artesunate-amodi- aquine groups by drug comparator Figure 7
Overall risks of gametocyte appearance in artesu-
nate-amodiaquine groups by drug comparator. Note: 
The forest plot represents the risk of failure of artesunate 
amodiaquine versus comparators in randomized comparative 
studies. Results were stratified by site. The size of boxes is 
proportional to the number of patients included. The square 
represents the adjusted hazard ratio and 95% CI.
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Conversely, AS+SP (57/1000 PGW) increased the overall
gametocyte carriage rate by 8% versus AS+AQ, but not sig-
nificantly so (53/1000 PGW, RRMH = 1.15, 95% CI 0.78–
1.69, p = 0.514, weighted by site).
Treating patients with AQ+SP significantly increased the
overall carriage rate by 101% from 36/1000 to 72/1000
PGW vs. AS+AQ (RRMH = 1.95, 95% CI 1.56–2.40, p =
0.001, weighted by site). Using CQ+SP (157/1000 PGW)
also increased the overall carriage rate by 194% compared
to AS+AQ (53/1000 PGW, RRMH = 3.00, 95% CI 3.36–
3.71, p = 0.001, weighted by site). Overall gametocyte car-
riage with AQ alone (45/1000 PGW) was also superior by
209% compared to AS+AQ combination (15/1000 PGW,
RRMH = 3.34, 95% CI 1.97–5.71, p = 0.001, weighted by
site).
Anaemia
The prevalence of anaemia at baseline was 49.4% (5031/
10194), ranging from low levels (2.9%, 4/140) in Sen-
egal-Mlomp, to high levels (86.7%, 91/105) in Zanzibar-
Micheweni.
Predictors of anaemia. Using multivariate analysis and
controlling for sites, patients in the AS&AQ group who
had gametocyte on admission were at a higher risk for
anaemia (AOR = 1.56, 95% CI 1.23–1.98, p = 0.001), as
were younger children (AOR = 0.66, 95% CI 0.62–0.70, p
= 0.001).
Effects of AS&AQ treatment on anaemia in randomized
trials. In patients treated with AS&AQ and followed until
Day 28, 62% (1,764/2,863) were anaemic at enrolment.
Of these, 25% (709/2,863) had mild (8–9.9 g/dL, grade
2), 26% (745/2,863) moderate (5–7.9 g/dL, grade 3) and
11% (310/2,863) severe anaemia (<5 g/dL, grade 4). By
Day 28, 38% (678/1,764) of the patients had recovered,
62% (1,086/1,764) remained anaemic, and 9% (104/
1,099) who were not anaemic on admission became
anaemic (of which 9% [9/104] had severe anaemia). For
88% (274/310) of the patients who had severe anaemia
on admission, the severity of anaemia was reduced. By
Day 28, anaemia in these 274 patients became moderate
in 273 patients (99%) and mild in 1 patient (<1, 1/274).
Severe anaemia remained unchanged in 12% (36/310).
Overall, less than 1% (9/2553) of the patients developed
severe anaemia post treatment. Paired analysis of Day 0
and Day 7 showed a significant transient decline in Hgb
count (-28 g/dL, SD 1.17, -3%, 95% CI -5 to -1, p = 0.001)
followed by a significant increase on Day 28 (+1.16 g/dL,
SD 1.63, +13%, 95% CI 12 – 15, p = 0.001) compared to
Day 0.
Results by drug treatment (Table 5).
In randomized comparative trials, in patients followed up
until Day 28, 46% (353/762) in the AS&AQ groups, and
32% (246/471) of the patients in the AL groups were
anaemic on admission (p = 0.044). On Day 28, in AS&AQ
groups, 54% (190/353) of the patients recovered, 46%
(163/353) remained anaemic, and 10% (39/409) who
were not anaemic on admission became anaemic (none
had severe anaemia <5 g/dL). On Day 28, in the AL
groups, 56% (138/246) recovered from anaemia, 44%
(108/246) remained anaemic, and 8% (19/225) became
anaemic (none had severe anaemia). There was no differ-
ence in proportions of patients recovering, remaining, or
becoming anaemic between these groups. A paired analy-
sis of Days 0 and 7 showed a significant transient decline
in both groups in Hgb count (-5%, 95% CI -3 to -7, p =
0.001; -2%, 95% CI -4 to -1, p = 0.004, respectively). The
mean paired difference decrease was greater in AS&AQ
compared to AL groups (p = 0.001). By Day 28, the rela-
tive mean paired difference increased significantly in both
groups with no difference between the two groups (+9%,
95% CI +7 to +11, p = 0.001; +10%, 95% CI +7 to +12, p
= 0.001, respectively; p = 0.917).
Similar paired analysis results of Day 0 and Day 14 (Table
5) were observed in randomized comparative trials with
AQ+SP and DP, as well between Days 0 and 28 in patients
treated with AS&AQ (p = 0.001 for all comparisons). No
significant differences were observed in variations of Hgb
between treatment arms, except in Rwanda [13] where the
recovery in relative mean paired Hct difference in the
AS+AQ group (+10%, 95% CI 8 to 11) was significantly
higher than in the DP group (6%, 95% CI 4 to 8) (p =
0.021).
In trials comparing AS+SP and AS+AQ (Table 5), a similar
transient decrease was observed in various settings on Day
7 until recovery on Day 28 (+13% for both comparisons)
without any variation difference comparing the drugs
(Day 7: p = 0.372, Day 28: p = 0.772).
In Uganda, there was no significant difference in haemo-
globin levels in the AS+AQ group on Day 14 compared to
Day 0 (-0.4%, p = 0.551) whereas in the comparative
AQ+SP group, a significant relative mean paired increase
was detected (+1.3%, p = 0.016). The mean paired differ-
ence between the two groups being significant (p =
0.039). On Day 28 the variation was no longer different
between the two groups (+15%, +16%, respectively, p =
0.406).
In Burkina Faso [5] no difference was detected between
the loose and the fixed AS&AQ combinations between
Days 0 and 28 (+17%, +18%, respectively, p = 0.946).Malaria Journal 2009, 8:203 http://www.malariajournal.com/content/8/1/203
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Discussion
This individual patient analysis has pooled data from 26
drug trials in a majority of paediatric malaria cases in sub-
Saharan Africa identified through a systematic search and
has focused on efficacy; safety will be reported separately.
The trials reported herein were conducted between July
1999 and December 2006; thus, this analysis provide
recent information on the current situation. Both absolute
and comparative efficacy results varied between crude and
PCR-adjusted results (i.e. whether reinfections are
counted or discounted in the analysis).
The WHO recommends using treatments that are at least
90% effective after discounting reinfections [2]. Overall,
AS&AQ had an efficacy of ~94% after excluding reinfec-
tions by PCR. However, 10 sites in eight countries (out of
28 sites in 16 countries) failed to meet the WHO, Day 28,
PCR-adjusted cut-off of >90% efficacy. These sites were in
Congo, DRC, Kenya, Sierra Leone, South Sudan, Rwanda,
Uganda, and Zanzibar. However, at other sites in some of
these countries (DRC, Rwanda, South Sudan, Uganda,
and Zanzibar), the PCR-adjusted efficacy exceeded 90%.
Moreover, the PCR-adjusted efficacy in the comparator
arm was >90% only in three sites (Kindamba-Congo,
Amudat-Uganda, Micheweni-Zanzibar), and was not sig-
nificantly superior to AS&AQ.
The definition of recrudescent failure was strict since
recurrent parasitaemia that could not be successfully gen-
otyped by PCR (indeterminate case) was considered con-
servatively as a recrudescent failure. This was done in
order to prevent from introducing overestimation bias in
assessing AS&AQ efficacy levels, in comparison to other
attrition methods by modified intent-to-treat analysis that
would increase the level of efficacy by excluding the PCR
indeterminate cases from the analysis. Compared to other
treatments, AS&AQ was either superior to non-ACTs or
not different from AS+SP and AL but inferior to DP.
Table 5: Haemoglobin and haematocrit values and changes between Day 0–14, and Day 0–28 (AS&AQ and comparators)
Haemoglobin N Day 0 Day 7 Paired relative difference Paired difference t-value P-value
mean sd Mean sd % lower 95%CI upper 95%CI mean sd
Ndiaye ASAQ 766 10.1 2.29 9.6 2.02 -5% -3% -7% -0.50 1.24 -11.07 0.000
AL 482 9.9 2.26 9.7 1.92 -2% 1% -4% -0.18 1.40 -2.89 0.004
Epicentre AS+AQ 249 10.3 1.76 9.8 1.74 -4% -1% -7% -0.42 1.19 -5.50 0.000
AS+SP 248 10.2 1.88 9.7 1.66 -5% -2% -8% -0.51 1.20 -6.71 0.000
Haematocrit N Day 0 Day 7 Paired relative difference Paired difference t-value P-value
mean sd Mean sd % lower 95%CI upper 95%CI mean sd
Sirima AS+AQ 136 25.5 4.93 27.4 4.57 7% 4% 10% 1.87 3.75 5.83 0.000
ASAQ 149 25.8 4.52 27.5 4.25 6% 4% 9% 1.64 3.12 6.40 0.000
Haematocrit N Day 0 Day 14 Paired relative difference Paired difference t-value P-value
mean sd Mean sd % lower 95%CI upper 95%CI mean sd
Karema AQ+SP 251 31.5 5.35 34.49 3.70 9% 8% 11% 2.95 4.95 9.44 0.000
AS+AQ 247 31.0 5.49 33.99 3.66 10% 8% 11% 3.02 4.88 9.72 0.000
DP 247 31.5 4.91 33.43 3.62 6% 4% 8% 1.90 5.24 5.70 0.000
Haemoglobin N Day 0 Day 28 Paired relative difference Paired difference t-value P-value
mean sd mean sd % lower 95%CI upper 95%CI mean sd
Ndiaye ASAQ 762 10.1 2.31 11.04 1.76 9% 7% 11% 0.96 1.74 15.48 0.000
AL 471 9.96 2.26 10.93 1.59 10% 7% 12% 0.97 1.69 12.52 0.000
Epicentre AS+AQ 798 9.60 1.93 10.68 1.59 11% 9% 13% 1.08 1.68 18.18 0.000
AS+SP 801 9.54 1.94 10.64 1.50 12% 10% 13% 1.10 1.66 18.77 0.000
Haematocrit N Day 0 Day 28 Paired relative difference Paired difference t-value P-value
mean sd mean sd % lower 95%CI upper 95%CI mean Sd
Sirima AS+AQ 259 26.7 6.00 31.38 4.50 18% 16% 20% 4.70 5.85 12.92 0.000
ASAQ 258 26.7 5.59 31.33 5.02 17% 15% 20% 4.66 5.78 12.94 0.000
Note. SD: standard deviation; CI: confidence intervalMalaria Journal 2009, 8:203 http://www.malariajournal.com/content/8/1/203
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As expected, the AS&AQ crude efficacy, which counts rein-
fections as failures, was much lower, ~78% (with wide
inter-country variability), than was the PCR-adjusted effi-
cacy (~94%). During the 28 days of follow-up, the quo-
tients of failure in the AS&AQ groups were the greatest on
Day 21 and Day 28, in contrast with the other forms of
ACT, for which the peak was reached on Day 28. When the
risk of a reinfection is high in areas of intense transmis-
sion, treatment with longer post-treatment protection
(AL, AS+SP, DP) fared better than AS&AQ. This probably
reflects the relatively shorter residence time of AQ in the
human body such that concentrations of the active metab-
olite, monodesethyl-amodiaquine, might be lower or
absent when a reinfection occurs compared to other part-
ner drugs combined to artemisinin derivatives. In the
crude analysis of efficacy, AS&AQ was inferior to DP, AL
and AS+SP.
Whether a short or a longer residence time for a drug is
preferable is a matter of debate. Operationally, post-treat-
ment protection against reinfection is a positive feature as
it minimizes the number of treatments needed by the
individual, the frequency of contacts with health provid-
ers, the risk of cumulative toxicity, and the costs (direct
and indirect) incurred by households and health systems.
Conversely, persisting concentrations of low drug levels
may be insufficient to inhibit the replication of parasites
arising from a new infection and potentially select for the
parasites that can tolerate those levels. Furthermore,
results depend on the study design and the duration of
follow-up. It might be difficult to judge the operational
implications of reinfections and re-treatment based on
studies of treatment of single episodes of malaria; pro-
spective cohort studies are best suited to assess the conse-
quences of repeat treatments.
Based on the Day 28 efficacy results of these studies,
AS&AQ would be suitable according to WHO standards as
a potential alternative treatment for P. falciparum malaria
in Angola, Burkina Faso, and Mali, where the current first
line is AL. AS&AQ satisfied the criteria for continued use
in some of the countries where is the current first-line
treatment (Cameroon, Guinea, Madagascar, Gabon, Sen-
egal, and Zanzibar), but AS&AQ would not qualify in
some sites in Sierra Leone, Congo, DRC, North and South
Sudan, Rwanda, Kenya, Uganda. However, where the
AS&AQ efficacy PCR-adjusted was <90%, and the one of
the comparators was >90%, the comparator groups were
never significantly superior to AS&AQ whether in Congo
(AL), Rwanda (DP), or Uganda (AS+SP).
This multi-centre analysis provides also interesting infor-
mation on malaria and response to treatment. It confirms
that children under 5 years of age are particularly vulner-
able, as they are more likely to have on presentation
higher baseline parasitaemia, be anaemic and carry game-
tocytes, and have a higher risk of failure compared to
older children for all treatments evaluated, consistent
with a lack of malaria-acquired immunity [44].
Being young and anaemic increases the risk for antimalar-
ial treatment to fail to clear parasites and to be reinfected
after clearing the current infection, suggesting a relation-
ship between anaemia and transmission intensity, and
between anaemia and susceptibility to infection. Con-
versely, young age alone predicts recrudescence after ini-
tial clearance.
Young children are a major reservoir of gametocytes and
hence the engine of malaria transmission. Gametocyte
carriage is highest when asexual parasitaemia is low.
Fever clearance was fast with AS&AQ, similar to other
forms of ACT and AQ+SP, but faster than AL, and other
non-ACT. Parasite clearance was fast with AS&AQ, gener-
ally faster than non-ACT and similar to other forms of
ACT.
The presence of gametocytes on admission ranged from 0
to ~50% across the studies, and was related to young age
and low asexual parasitaemia. The cumulative risk of
gametocytes appearing post-treatment was ~20% with 36
PGW carriage per 1000 weeks of follow-up. The gameto-
cyte clearance time in AS&AQ groups was the same
(median 14 days) whether patients presented with game-
tocytes or developed gametocytaemia thereafter, but the
peak distributions of time to clearance were Day 2 and
Day 14, respectively. Compared to AS&AQ, the risk of
appearance of gametocytes was higher and the carriage
duration was longer with the non-ACTs and AS+SP, but
lower with DP and AL in one Ugandan site, consistent
with their better efficacy against asexual parasites.
Endemic countries are faced with the challenge of identi-
fying the treatment(s) best adapted to their needs. To
inform decisions, both locally generated data and more
general information are needed. Systematic reviews and
meta-analyses are useful to summarize evidence and assist
policy makers. Pooling individual patient data offers
advantages over aggregate patient data meta-analysis
because it allows standardizing patient attrition and anal-
yses. Each study can then be re-analysed based on com-
mon criteria for efficacy and safety and different drug
regimens can be combined and compared. Data can also
be combined and analysed together while stratifying by
site. Efficacy analyses can be done on modified intent-to-
treat basis of all randomized patients and use Kaplan-
Meier product-limit estimates of time to event. This is now
the preferred analytical method for anti-malarial drug effi-
cacy trials [45].Malaria Journal 2009, 8:203 http://www.malariajournal.com/content/8/1/203
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Individual studies are not usually designed and, therefore,
not powered to detect differences in a variety of secondary
outcomes (e.g. gametocyte carriage, parasite or fever clear-
ance time). Results of this analysis of individual patient
data were presented using similar methods to that used
for a conventional meta-analysis of trials (for instance in
Cochrane's review) with graphical representation of risks,
recommended for communicating in medical research
[46]. Compared to a meta-analysis from published stud-
ies, combining and standardizing these data at patient
level increases statistical power by facilitating analytical
practice (sub-group and multivariate analyses stratified by
site) despite significant heterogeneity between trials. It
also enables standardized estimates of drug efficacy across
different studies, and the identification of at-risk groups to
help target public health strategies.
However, this individual patient multi-centre analysis is
not without limitations. First, the analysis included only
half, 25 of the 46 trials that met criteria of quality for
inclusion. It also has excluded additional trials published
past August 2008, due to the time needed to adequately
harmonize published data, obtain additional reported
data and conduct the analyses. This might be a source of
bias. The Worldwide Antimalarial Resistance Network
(WARN) [47,48] intends to create a living database, which
might become the basis for updated assessments of drug
efficacy. Second, these results apply primarily to children
under five years of age (75% of the patients enrolled) and
less to older children or adults. However, young children
are indeed those at higher risk and are the primary target
of malaria interventions. Finally, this analysis showed het-
erogeneity of study results both across and within coun-
tries, a finding that illustrates the challenges faced when
making drug policy decisions. Differences in efficacy
between sites might have resulted from the variability in
the composition of the study drug, as well as PCR meth-
ods that have been used according to sites facilities.
A Cochrane systematic review and meta-analysis which
includes AS&AQ [49] has just been published with con-
sistent results.
At a bare minimum, malaria control programmes need
up-to-date, dynamic, and comparative data on anti-malar-
ial drug efficacy and safety in order to recommend opti-
mal drug treatments for their countries. Prospective multi-
centre analysis could be a key element for deciding drug
policy at national and regional levels.
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